A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Condition: Sarcoma, Ewing Intervention: Biological: TK216+Vincristin Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 16, 2021 Category: Research Source Type: clinical trials